VCRE Vicore Pharma Holding AB
$9.40▲ +0.21%
Healthcare
Other
Volume 4.0K
Avg Volume (10D) 30.0K
Key Metrics & Fundamentals
Market Cap
$264.75M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.88 - 17.80
% vs 50 MA
-9.03%
% vs 200 MA
–%
RSI-14
47.1
MACD Histogram
+0.1500
Beta (1Y vs SPY)
0.49
Free Cash Flow
-$155.92M
Gross Rev
$2.21M
Gross Profit
$2.21M
EBITDA
-$142.67M
COGS
–
Operating Exp
$152.32M
Operating Income
-$150.10M
EBIT
-$150.10M
Pretax Income
-$142.67M
Net Income
-$142.84M
EPS (Diluted)
-5.10
Price & Volume History
Loading chart…
Recent News
Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results
ACCESS Newswire · Oct 22, 2026 1:05 PM ET
Vicore Pharma to Participate in the Chardan Healthcare Conference
ACCESS Newswire · Oct 13, 2026 2:20 AM ET
Jefferies Initiates Vicore Pharma Holding at Buy With $25 Price Target
MT Newswires · Oct 9, 2026 7:28 AM ET
Increase in Number of Shares and Votes in Vicore Pharma
ACCESS Newswire · Sep 30, 2026 3:20 AM ET
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
ACCESS Newswire · Sep 17, 2026 2:20 AM ET
Vicore Pharma to Participate in Upcoming Healthcare Conferences
ACCESS Newswire · Sep 1, 2026 2:20 AM ET
Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference
ACCESS Newswire · Aug 26, 2026 2:20 AM ET
Vicore Pharma to Present at the European Respiratory Society Congress 2026
ACCESS Newswire · Aug 24, 2026 2:15 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VCRE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.